Selection of peptide inhibitor to matrix Metalloproteinase-2 using phage display and its effects on pancreatic cancer cell lines PANC-1 and CFPAC-1

International Journal of Biological Sciences

Volumn 8, Issue 5, 2012, Pages 650-662

  Lu, Gao ^a   Zheng, Maqing ^a   Zhu, Yunxia ^a   Sha, Min ^a   Wu, Yue ^a   Han, Xiao ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

M204C4; M205C4; MMP 2; Pancreatic cancer; Peptide; Phage display

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE A; M204C4 PEPTIDE; M205C4 PEPTIDE; OLIGOPEPTIDE; PEPTIDE; PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CANCER INVASION; CANCER TRANSPLANTATION; DRUG ANTAGONISM; HUMAN; MOLECULAR GENETICS; MOUSE; PANCREAS TUMOR; PEPTIDE LIBRARY; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; PEPTIDE LIBRARY; PEPTIDES; PROTEASE INHIBITORS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84863770271     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.3897     Document Type: Article

References (46)

1. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999; 43 Suppl:S42-51.
2. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2(3):161-174.
3. Itoh T, Tanioka M, Yoshida H, et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998; 58(5):1048-1051.
4. Berglin L, Sarman S, van der Ploeg I, et al. Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. Invest Ophthalmol Vis Sci. 2003; 44(1):403-408.
5. Takahashi M, Fukami S, Iwata N, et al. In vivo glioma growth requires host-derived matrix metalloproteinase 2 for maintenance of angioarchitecture. Pharmacol Res. 2002; 46(2):155-163.
6. Kato T, Kure T, Chang JH, et al. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett. 2001; 508(2):187-190.
7. Ohno-Matsui K, Uetama T, Yoshida T, et al. Reduced retinal angiogenesis in MMP-2-deficient mice. Invest Ophthalmol Vis Sci. 2003; 44(12):5370-5375.
8. Pellikainen JM, Ropponen KM, Kataja VV, et al. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 2004; 10(22):7621-7628.
9. Atkinson JM, Pennington CJ, Martin SW, et al. Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: correlation of MMP-14 mRNA expression and proteolytic activity. Eur J Cancer. 2007; 43(11):1764-1771.
10. Ellenrieder V, Alber B, Lacher U, et al. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer. 2000; 85(1):14-20.
11. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 2005; 87(3-4):287-297.
12. Overall CM, Kleifeld O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006; 6(3):227-239.
13. Pei D, Kang TQi H. Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J Biol Chem. 2000; 275(43):33988-33997.
14. Wallon UM, Overall CM. The hemopexin-like domain (C domain) of human gelatinase A (matrix metalloproteinase-2) requires Ca2+ for fibronectin and heparin binding. Binding properties of recombinant gelatinase A C domain to extracellular matrix and basement membrane components. J Biol Chem. 1997; 272(11):7473-7481.
15. Mazzoni A, Mannello F, Tay FR, et al. Zymographic analysis and characterization of MMP-2 and-9 forms in human sound dentin. J Dent Res. 2007; 86(5):436-440.
16. M D, Brooks SA. In Vitro Invasion Assay Using Matrigel(R). Methods Mol Med. 2001; 58:61-70.
17. Saad RS, Kordunsky L, Liu YL, et al. Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol. 2006; 19(10):1317-1323.
18. Su D, Deng H, Zhao X, et al. Targeting CD24 for treatment of ovarian cancer by short hairpin RNA. Cytotherapy. 2009; 11(5):642-652.
19. Yang JZ, Bastian KC, Moore RD, et al. Quantitative analysis of a model opioid peptide and its cyclic prodrugs in rat plasma using high-performance liquid chromatography with fluorescence and tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 780(2):269-281.
20. Guo S, Duan JA, Tang YP, et al. Characterization of nucleosides and nucleobases in fruits of Ziziphus jujuba by UPLC-DAD-MS. J Agric Food Chem. 2010; 58(19):10774-10780.
21. Su S, Guo J, Duan JA, et al. Ultra-performance liquid chromatography-tandem mass spectrometry analysis of the bioactive components and their metabolites of Shaofu Zhuyu decoction active extract in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878(3-4):355-362.
22. Zahner G, Harendza S, Muller E, et al. Prostaglandin E2 stimulates expression of matrix metalloproteinase 2 in cultured rat mesangial cells. Kidney Int. 1997; 51(4):1116-1123.
23. Ito H, Duxbury M, Benoit E, et al. Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res. 2004; 64(20):7439-7446.
24. Schultz RM, Merriman RL, Toth JE, et al. Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res. 1993; 5(6-7):223-228.
25. Belotti D, Paganoni P, Manenti L, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003; 63(17):5224-5229.
26. Munaut C, Noel A, Hougrand O, et al. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer. 2003; 106(6):848-855.
27. Wearley LL. Recent progress in protein and peptide delivery by noninvasive routes. Crit Rev Ther Drug Carrier Syst. 1991; 8(4):331-394.
28. Adessi C, Frossard MJ, Boissard C, et al. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J Biol Chem. 2003; 278(16):13905-13911.
29. Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006; 30(4):351-367.
30. Somiari SB, Somiari RI, Heckman CM, et al. Circulating MMP2 and MMP9 in breast cancer--potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer. 2006; 119(6):1403-1411.
31. Stahtea XN, Roussidis AE, Kanakis I, et al. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. Int J Cancer. 2007; 121(12):2808-2814.
32. Bloomston M, Zervos EERosemurgy AS, 2nd. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol. 2002; 9(7):668-674.
33. Prager GW, Lackner EM, Krauth MT, et al. Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. Mol Oncol. 2010; 4(2):150-160.
34. Hesek D, Toth M, Meroueh SO, et al. Design and characterization of a metalloproteinase inhibitor-tethered resin for the detection of active MMPs in biological samples. Chem Biol. 2006; 13(4):379-386.
35. Xu X, Mikhailova M, Chen Z, et al. Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2). Matrix Biol. 2011; 30(7-8):404-412.
36. Hu J, Dubois V, Chaltin P, et al. Inhibition of lethal endotoxin shock with an L-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library. Comb Chem High Throughput Screen. 2006; 9(8):599-611.
37. Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999; 17(8):768-774.
38. Desjobert C, de Soultrait VR, Faure A, et al. Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase. Biochemistry. 2004; 43(41):13097-13105.
39. Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am. 2001; 10(2):383-392.
40. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 2001; 7(1):14-23.
41. Fang JH, Zhou HC, Zeng C, et al. MicroRNA-29b suppresses tumor angiogenesis, invasion and metastasis by regulating MMP-2 expression. Hepatology. 2011 Nov;54(5):1729-40.
42. Kargiotis O, Chetty C, Gondi CS, et al. Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma. Oncogene. 2008; 27(35):4830-4840.
43. Masson V. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis]. Bull Mem Acad R Med Belg. 2006; 161(5):320-326.
44. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005; 9(2):267-285.
45. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999; 103(9):1237-1241.
46. Katz MH, Takimoto S, Spivack D, et al. An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer. Clin Exp Metastasis. 2004; 21(1):7-12.